Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study
Open Access
- 1 January 2026
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Abstract
Background: The optimal timing of anticoagulation initiation after acute ischemic stroke (AIS) in patients with non-valvular atrial fibrillation (NVAF) remains uncertain. We evaluated the association between early versus delayed rivaroxaban initiation and clinical outcomes in this population. Methods: In this retrospective, single-center cohort study, 401 hospitalized AIS patients with NVAF receiving rivaroxaban between January 2019 and June 2024 were classified into early (≤7 days) or delayed (>7 days) initiation groups. Primary outcomes were excellent [modified Rankin Scale (mRS) 0-1] and good (mRS 0-2) functional outcomes at 90 days and 12 months. Secondary outcomes included recurrent ischemic stroke, clinically relevant major bleeding, all-cause mortality, composite outcomes, and in-hospital length of stay (LOS). Inverse probability of treatment weighting (IPTW) was applied, followed by regression analyses. Sensitivity and subgroup analyses were performed. Results: After IPTW adjustment, early rivaroxaban initiation was associated with a higher likelihood of achieving mRS 0-1 at 90 days (aOR 1.76, 95% CI 1.02-3.05) and 12 months (aOR 1.82, 95% CI 1.08-3.06), as well as a shorter LOS. No significant differences were observed for mRS 0-2 or other secondary outcomes. Sensitivity analyses yielded consistent results, and subgroup analyses suggested a trend toward greater benefit among patients with higher baseline stroke severity (NIHSS >7). Conclusion: Early rivaroxaban initiation after AIS in patients with NVAF was associated with improved excellent functional outcomes without an apparent increase in adverse events, supporting its potential feasibility in routine practice and warrant confirmation in larger prospective studies.Keywords
Funding Information
- the Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2023-LCYJ-PY-24)
- Project of China Hospital Reform and Development Research and Development Research Institute, Nanjing University (NDYGN2023007)
- Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation (NDYGN2023007)
This publication has 45 references indexed in Scilit:
- Early start of DOAC after ischemic strokeNeurology, 2016
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal, 2016
- Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanismThrombosis and Haemostasis, 2016
- National Institutes of Health Stroke Scale (NIHSS)Journal of Physiotherapy, 2014
- Rivaroxaban vs. Warfarin in Japanese Patients With Atrial FibrillationCirculation Journal, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analysesBMJ, 2010
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005